[ad_1] Vertex Pharmaceuticals (NASDAQ:VRTX) has worked closely with CRISPR Therapeutics (NASDAQ:CRSP) for quite a while to develop a CRISPR gene-editing therapy targeting rare blood diseases. Recently, Vertex expanded a partnership focused on CRISPR gene editing, but it’s not with CRISPR Therapeutics. In this Motley Fool Live video recorded on Aug. 25, 2021, Motley Fool contributors